**BUSINESS HIGHLIGHTS**

**THIRD-QUARTER 2022 RESULTS**

**TOTAL COMPANY**

- **$10.4B** SALES WORLDWIDE
- +1.3%¹ ON AN ORGANIC BASIS*

- **$1.15**² ADJUSTED DILUTED EPS

**RAISING FULL-YEAR 2022 EPS GUIDANCE**

- **$5.17 to $5.23**³ Adjusted Diluted EPS

**BUSINESS UNIT SALES**

- **$3.6B** MEDICAL DEVICES
- **$3.7B** DIAGNOSTICS
- **$1.3B** ESTABLISHED PHARMACEUTICALS
- **$1.8B** NUTRITION

**BUSINESS HIGHLIGHTS**

**STAYING AHEAD OF VIRAL THREATS**

- U.S. FDA Emergency Use Authorization for Monkeypox PCR test used with Alinity™ m System
- The Abbott Pandemic Defense Coalition, a first-of-its-kind scientific and public health partnership, is dedicated to the early detection of and rapid response to viral threats

**INNOVATING FOR PATIENTS AND DOCTORS**

- European launch of Amplatzer™ Talisman™ PFO Occlusion System
- System treats people with a patent foramen ovale (PFO) — a hole in the heart that doesn’t close following birth — who have experienced a stroke and are at risk of having another

**UNITING HEALTH AND TECH IN DIABETES CARE**

- New data show FreeStyle Libre™ system reduces diabetes-related hospitalizations for people with Type 2 diabetes on once-daily insulin therapy⁴
- U.S. launch of FreeStyle Libre 3 system, including the world’s smallest and thinnest² wearable sensor

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.